About Us
Transradial Technologies, Inc. is a medical device company developing a novel radial closure system revolutionizing vascular closure with its novel SĀPH system—Suction Activated Patent Hemostasis. Designed to overcome the limitations of traditional compression bands, designed to preserve arterial flow, improve patient comfort, and reduce staff burden.
The device has demonstrated zero radial artery occlusions in early clinical use and is currently in a 50-patient trial, with a 510(k) submission targeted for Q1 2026. SĀPH is uniquely positioned for accelerated growth in the radial closure space, as well as for acquisition by major strategic players.
Collectively, the Transradial Technologies leadership team has achieved five successful exits worth over $1B, guided multiple acquisitions, and built companies that have shaped interventional cardiology and medical device markets worldwide.
Mission
At Transradial Technologies, our mission is to transform vascular access and closure by delivering innovative, patient-focused solutions that improve outcomes, enhance comfort, and streamline clinical workflows. We are committed to advancing interventional cardiology through devices and technologies that combine clinical rigor, simplicity, and innovation.
Vision
Our vision is to establish the new standard of care in transradial closure by ensuring safe, fast, and reliable hemostasis while preserving arterial patency. Designed to eliminate radial artery occlusion and reducing workflow burden, SĀPH aims to improve patient outcomes, staff efficiency, and the overall cath lab experience worldwide.
Meet the Team
-
Randy Hubbell
CEO
Randy is a proven leader in medical technologies with a track record of successfully commercializing transformational devices and globalizing businesses for both Johnson & Johnson and Boston Scientific. He has held key leadership roles including:
-Vice President, Worldwide Marketing at Johnson & Johnson
-Chairman, President & CEO at Carmell Corporation (NASDAQ: CTCX)
-Chief Commercial Officer at Cardiva Medical, Inc. (acquired by Haemonetics)
-Randy holds a B.S. in Computer Science from Tulane University and an MBA from Loyola University of New Orleans.
-
Ron Caputo, MD, FACC, FSCAI
Medical Director, Co-Founder & Co-Inventor
Dr. Ronald P. Caputo is an interventional cardiologist with more than three decades of experience advancing cardiovascular care. He is board certified in cardiovascular disease and invasive/interventional cardiology and has authored over 90 peer-reviewed publications. Dr. Caputo previously co-founded Angiolink Corporation, a medical device company acquired by Medtronic (NYSE: MDT), and has been a leader in physician- driven innovation and clinical research throughout his career.
-Recognized thought leader in interventional cardiology
-Pioneered transradial arterial access in the U.S., performing his first radial cases in 1997 and driving adoption of radial-first strategies through leadership in SCAI and clinical device innovation
-Experienced clinical researcher and innovator
-Deep expertise in developing physician-driven solutions
-
Steve Green
President, Co-Founder & Co-Inventor
Steve is a 40-year veteran of medical device design and innovation with extensive experience leading product development and commercialization. He is the inventor on more than 20 U.S. and international patents.
-Former CTO of Blackstone Medical, Inc. (acquired by Orthofix International N.V.)
-Proven record of creating breakthrough devices adopted globally
-Decades of leadership across R&D, operations, and commercialization
-
David P. Koch
Chief Commercial Officer
David brings more than 25 years of success leading high-performance sales and marketing teams across both Fortune 50 companies and high-growth startups. He has earned the highest commercial honors at Abbott Laboratories, Johnson & Johnson, Hologic, and Cardiva Medical, Inc., consistently delivering profitable growth, market expansion, and exceeding revenue expectations.
-Expertise in building and scaling commercial organizations
-Record of maximizing talent, reducing costs, and driving team performance
-Proven results in commercializing products in both global enterprises and entrepreneurial ventures